Arjun Gupta1, Ambarish Pandey2, Colby Ayers3, Muhammad S Beg4, Susan G Lakoski5, Gloria L Vega6, Scott M Grundy6, David H Johnson1, Ian J Neeland7. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. 2. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX. 3. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. 4. Division of Oncology, University of Texas Southwestern Medical Center, Dallas, TX. 5. Department of Clinical Cancer Prevention and Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX. 6. Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX. 7. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: ian.neeland@utsouthwestern.edu.
Abstract
OBJECTIVE: To examine the association between specific adipose tissue depots and the risk of incident cancer in the Dallas Heart Study. PATIENTS AND METHODS: Individuals without prevalent cancer in the Dallas Heart Study underwent quantification of adipose depots: visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue, and liver fat by magnetic resonance imaging, and subcutaneous lower-body fat (LBF) by dual-energy X-ray absorptiometry from January 1, 2000, through December 31, 2002, and were observed for the development of cancer for up to 12 years. Multivariable Cox proportional hazards modeling was performed to examine the association between fat depots and cancer. RESULTS: Of 2627 participants (median age, 43 years; 69% nonwhite race), 167 (6.4%) developed cancer. The most common primary sites of cancer were the breast (in women) and the prostate (in men). In multivariable models adjusted for age, sex, race, smoking, alcohol use, family history of malignancy, and body mass index, a 1-SD increase in VAT was not associated with increased risk of cancer (hazard ratio [HR], 0.94; 95% CI, 0.77-1.14). In contrast, each 1-SD increase in LBF was associated with a reduced incidence of cancer (HR, 0.69; 95% CI, 0.52-0.92) in the fully adjusted model. CONCLUSIONS: In this study, adiposity-associated cancer risk was heterogeneous and varied by fat depot: VAT was not independently associated with incident cancer, and LBF seemed to protect against cancer development. Further studies of the adiposity-cancer relationship, including serial assessments, are needed to better elucidate this relationship.
OBJECTIVE: To examine the association between specific adipose tissue depots and the risk of incident cancer in the Dallas Heart Study. PATIENTS AND METHODS: Individuals without prevalent cancer in the Dallas Heart Study underwent quantification of adipose depots: visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue, and liver fat by magnetic resonance imaging, and subcutaneous lower-body fat (LBF) by dual-energy X-ray absorptiometry from January 1, 2000, through December 31, 2002, and were observed for the development of cancer for up to 12 years. Multivariable Cox proportional hazards modeling was performed to examine the association between fat depots and cancer. RESULTS: Of 2627 participants (median age, 43 years; 69% nonwhite race), 167 (6.4%) developed cancer. The most common primary sites of cancer were the breast (in women) and the prostate (in men). In multivariable models adjusted for age, sex, race, smoking, alcohol use, family history of malignancy, and body mass index, a 1-SD increase in VAT was not associated with increased risk of cancer (hazard ratio [HR], 0.94; 95% CI, 0.77-1.14). In contrast, each 1-SD increase in LBF was associated with a reduced incidence of cancer (HR, 0.69; 95% CI, 0.52-0.92) in the fully adjusted model. CONCLUSIONS: In this study, adiposity-associated cancer risk was heterogeneous and varied by fat depot: VAT was not independently associated with incident cancer, and LBF seemed to protect against cancer development. Further studies of the adiposity-cancer relationship, including serial assessments, are needed to better elucidate this relationship.
Authors: Muhammad Shaalan Beg; Sadia Saleem; Aslan Turer; Colby Ayers; James A de Lemos; Amit Khera; Philipp E Scherer; Susan G Lakoski Journal: J Natl Compr Canc Netw Date: 2015-07 Impact factor: 11.908
Authors: Rachel A Murphy; Taylor F Bureyko; Iva Miljkovic; Jane A Cauley; Suzanne Satterfield; Trisha F Hue; Heidi D Klepin; Steven R Cummings; Anne B Newman; Tamara B Harris Journal: Appl Physiol Nutr Metab Date: 2013-12-04 Impact factor: 2.665
Authors: Kathryn A Britton; Joseph M Massaro; Joanne M Murabito; Bernard E Kreger; Udo Hoffmann; Caroline S Fox Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: Alvin Chandra; Ian J Neeland; Jarett D Berry; Colby R Ayers; Anand Rohatgi; Sandeep R Das; Amit Khera; Darren K McGuire; James A de Lemos; Aslan T Turer Journal: J Am Coll Cardiol Date: 2014-09-09 Impact factor: 24.094
Authors: Klara J Rosenquist; Joseph M Massaro; Alison Pedley; Michelle T Long; Bernard E Kreger; Ramachandran S Vasan; Joanne M Murabito; Udo Hoffmann; Caroline S Fox Journal: J Clin Endocrinol Metab Date: 2015-01 Impact factor: 5.958
Authors: Arjun Gupta; Yehuda Herman; Colby Ayers; Muhammad S Beg; Susan G Lakoski; Shuaib M Abdullah; David H Johnson; Ian J Neeland Journal: PLoS One Date: 2016-09-16 Impact factor: 3.240
Authors: Ian J Neeland; Shruti Singh; Darren K McGuire; Gloria L Vega; Thomas Roddy; Dermot F Reilly; Jose Castro-Perez; Julia Kozlitina; Philipp E Scherer Journal: Diabetologia Date: 2018-08-29 Impact factor: 10.122
Authors: Sarah A Purcell; Camila L P Oliveira; Michelle Mackenzie; Paula Robson; John D Lewis; Carla M Prado Journal: Adv Nutr Date: 2022-08-01 Impact factor: 11.567
Authors: Gertraud Maskarinec; Michelle Ciba; Dan Ju; John A Shepherd; Thomas Ernst; Anna H Wu; Kristine R Monroe; Unhee Lim; Lynne R Wilkens; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-14 Impact factor: 4.090